The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA Sebastiaan Vastert – University Medical Center Utrecht
9:00 AM – 11:00 AM ET
Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA) Claudia Bracaglia, MD – IRCCS Ospedale Pediatrico Bambino Gesu'
9:00 AM – 11:00 AM ET
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Claudia Bracaglia, MD – IRCCS Ospedale Pediatrico Bambino Gesu'
9:00 AM – 11:00 AM ET
Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia Michael Zhang, MD, PhD – UPMC
9:00 AM – 11:00 AM ET
IL-18: A Biomarker That Reflects Disease Activity, Could It Be the Next Disease Activity Measure in Systemic Juvenile Idiopathic Arthritis? Shima Yasin, MD, MSc – Cincinnati Children's Hospital Medical Center
9:00 AM – 11:00 AM ET
Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry Ginger Janow, MD, MPH – Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health
9:00 AM – 11:00 AM ET
Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis Emely Verweyen, PhD – Cincinnati Children's Hospital
9:00 AM – 11:00 AM ET
Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis Gabriella Giancane, MD, PhD – IRCCS Gaslini
9:00 AM – 11:00 AM ET
Comparison of Immunological Biomarkers and Lung Histology in Patients with Elevated IL18 - Pulmonary Alveolar Proteinosis and Recurrent Macrophage Activation Syndrome (IL-18PAP-MAS) and Other Inflammatory Lung Diseases Alhanouf Alsaleem, MD, MBBS – KFSH&RC
9:00 AM – 11:00 AM ET
Health and Socioeconomic Outcomes in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed for a Median of Fifteen Years Sara Alehashemi, MD, MPH – NIH/NIAID/TADS
9:00 AM – 11:00 AM ET
Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI) Sofia Torreggiani, MD – National Institutes of Health
9:00 AM – 11:00 AM ET
Novel STING1 Mutations Including in the Transmembrane Linker Region Cause STING-associated Vasculopathy with Onset in Infancy (SAVI) Dana Kahle, BS – NIH
9:00 AM – 11:00 AM ET
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis Aleksander Lenert, MD, MS, FRCPC – University of Iowa
9:00 AM – 11:00 AM ET
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis Farzana Nuruzzaman, MD – Stony Brook Children's Hospital
9:00 AM – 11:00 AM ET
Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi-national 450 Case-Control Study Yongdong Zhao, MD, PhD – University of Washington
9:00 AM – 11:00 AM ET
Predictors of Colchicine Response in Patients with Undefined Systemic Autoinflammatory Diseases Mariana Correia Marques, MD – UPMC Children`s Hospital of Pittsburgh
9:00 AM – 11:00 AM ET
Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients Katelin R. Honer – National Institutes of Health
9:00 AM – 11:00 AM ET
Validation of Healthcare Claims Algorithms for Identification of Herpes Zoster Among Children with Autoimmune/Autoinflammatory Disease Beth Rutstein, MD – The Children's Hospital of Philadelphia
9:00 AM – 11:00 AM ET
Use of Rituximab to Treat COPA Syndrome: A Multi-Institutional Cohort Leigh A. Stubbs, MD – Baylor College of Medicine
9:00 AM – 11:00 AM ET
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score Suzanne Li, MD, PhD – Hackensack Meridian School of Medicine
9:00 AM – 11:00 AM ET
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma Suzanne Li, MD, PhD – Hackensack Meridian School of Medicine
9:00 AM – 11:00 AM ET
Three-Dimensional Analysis of Facial Asymmetry in Craniofacial Scleroderma Daniel H. Glaser, MD – UPMC Children's Hospital of Pittsburgh
9:00 AM – 11:00 AM ET
Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study Natalia Vasquez Canizares, MD – Children's Hospital at Montefiore
9:00 AM – 11:00 AM ET
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
9:00 AM – 11:00 AM ET
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma Gloria Lanzoni, MD – Department of Woman's and Child's Health, University of Padova
9:00 AM – 11:00 AM ET
No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
9:00 AM – 11:00 AM ET
HEADSS and Shoulders, Knees and Toes: Improving Sexual Orientation and Gender Identity Screening in the Pediatric Rheumatology Clinic Nayimisha Balmuri, MD – Hospital for Special Surgery
9:00 AM – 11:00 AM ET
Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease Ashley Danguecan, PhD – Hospital for Sick Children
9:00 AM – 11:00 AM ET
Identifying Targets to Improve the Assessment of Psychosocial Risk Factors in Adolescent Patients: Perspectives from Pediatric Rheumatology Fellows in the United States and Canada Jacob Spitznagle, MD – Hospital for Special Surgery
9:00 AM – 11:00 AM ET
Rheumatic Diseases in Mexican Children and Their Psychosocial and Economic Impact on Caregivers Fernando Garcia Rodriguez – Universidad Autónoma de Nuevo León
